Iliac Stents

Global Iliac Stents Market to Reach US$1.1 Billion by 2030

The global market for Iliac Stents estimated at US$916.7 Million in the year 2024, is expected to reach US$1.1 Billion by 2030, growing at a CAGR of 3.4% over the analysis period 2024-2030. Self-Expandable Stents Type, one of the segments analyzed in the report, is expected to record a 2.6% CAGR and reach US$580.6 Million by the end of the analysis period. Growth in the Balloon-Expandable Stents Type segment is estimated at 4.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$249.7 Million While China is Forecast to Grow at 6.2% CAGR

The Iliac Stents market in the U.S. is estimated at US$249.7 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$220.8 Million by the year 2030 trailing a CAGR of 6.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 2.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.9% CAGR.

Iliac Stents: Why Are They Pivotal in Managing Peripheral Artery Disease and Complex Vascular Conditions?

Global Iliac Stents Market – Key Trends & Drivers Summarized

The global iliac stents market is experiencing significant growth, fueled by the rising prevalence of peripheral artery disease (PAD), increased demand for minimally invasive vascular interventions, and ongoing advancements in stent technology. Iliac stents are deployed to treat occlusions or narrowing (stenosis) in the iliac arteries, which supply blood to the pelvis and lower limbs. This condition often stems from atherosclerosis and can lead to critical limb ischemia if left untreated. The demand for iliac stents is particularly strong in elderly populations and patients with comorbidities such as diabetes, hypertension, and hyperlipidemia—conditions that predispose individuals to vascular complications.

Recent years have seen a shift from open surgical repair to endovascular treatment (EVT), with iliac stenting becoming the gold standard due to its lower morbidity, shorter hospital stays, and quicker recovery. Market growth is also being supported by increasing access to vascular diagnostics, expanded health insurance coverage, and a rising number of PAD screening programs globally. In parallel, there is growing awareness among clinicians regarding early detection and aggressive treatment of iliac artery disease, especially in high-risk populations. These dynamics are contributing to a strong demand pipeline for stenting procedures and related devices in both developed and emerging healthcare markets.

What Technological Innovations Are Enhancing Iliac Stent Design and Outcomes?

Technological advancement in stent design and delivery systems is a key driver of market expansion. Manufacturers are continuously innovating to improve stent flexibility, radial strength, and long-term patency—especially in complex anatomical regions like the iliac bifurcation. Self-expanding stents, typically made of nitinol (a nickel-titanium alloy), are favored in tortuous or mobile arteries due to their conformability and resistance to external compression. Balloon-expandable stents, on the other hand, offer precision placement and higher radial force, making them suitable for heavily calcified or focal lesions. Hybrid stents that combine the benefits of both designs are also gaining traction.

Drug-eluting stents (DES) have emerged as a game-changer, releasing antiproliferative agents such as paclitaxel or sirolimus to reduce restenosis rates. While DES are more commonly used in coronary arteries, their application in peripheral settings—including the iliac arteries—is expanding due to favorable clinical outcomes. In addition, bioresorbable scaffolds and polymer-free coatings are under development to minimize long-term complications such as late stent thrombosis. Improved delivery systems, including low-profile catheters and hydrophilic coatings, are making it easier to navigate complex lesions and reduce procedure time. These innovations are making iliac stenting safer, more efficient, and more durable, while expanding eligibility to broader patient populations.

Where Is Market Demand for Iliac Stents Growing – And What’s Driving It?

North America and Western Europe continue to dominate the iliac stents market, owing to advanced healthcare infrastructure, high prevalence of PAD, and early adoption of novel vascular technologies. The U.S., in particular, is a key market due to robust clinical guidelines supporting endovascular interventions and extensive reimbursement coverage for PAD treatment. European countries such as Germany, France, and the UK also exhibit strong demand, driven by aging populations and proactive vascular screening initiatives.

The Asia-Pacific region is emerging as a high-growth market, with China, India, and Japan leading the charge. Factors such as growing public health awareness, expanding access to interventional cardiology and radiology services, and a rising burden of cardiovascular risk factors are driving increased procedural volumes. Furthermore, governments in these regions are investing in the development of tertiary healthcare facilities and rural outreach programs, enhancing access to PAD diagnosis and intervention. Latin America, the Middle East, and parts of Africa are also witnessing gradual uptake as medical tourism, insurance penetration, and healthcare infrastructure improve. Across all regions, increasing physician training and strategic partnerships between medical device manufacturers and hospitals are accelerating the diffusion of iliac stenting technologies.

The Growth in the Iliac Stents Market Is Driven by Several Factors…

The growth in the iliac stents market is driven by several factors related to disease prevalence, technological advancement, and end-use expansion. A primary driver is the rising global incidence of peripheral artery disease, fueled by aging demographics and lifestyle-related risk factors such as smoking, obesity, and sedentary behavior. As PAD becomes more common, the need for effective revascularization options like iliac stents continues to increase. In addition, improvements in diagnostic imaging—such as duplex ultrasonography, CT angiography, and MR angiography—are facilitating early and accurate identification of iliac artery stenosis.

Technological innovation remains a cornerstone of market expansion. The development of new stent platforms—offering enhanced deliverability, reduced restenosis, and longer durability—is attracting physician preference and improving clinical outcomes. End-use applications are also expanding beyond traditional vascular centers to include outpatient clinics and ambulatory surgical centers, enabled by the rise of low-profile, minimally invasive stent systems. Furthermore, favorable regulatory approvals, increasing clinical trial evidence, and growing payer support for endovascular procedures are driving broader adoption.

Lastly, global healthcare trends—such as the shift toward value-based care, increased patient awareness, and integration of artificial intelligence in vascular diagnostics—are reshaping how iliac artery disease is treated. These trends are reinforcing the strategic importance of iliac stents as a frontline therapy for PAD and ensuring sustained demand across regions, healthcare settings, and patient populations.

SCOPE OF STUDY:

The report analyzes the Iliac Stents market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Type (Self-Expandable Stents Type, Balloon-Expandable Stents Type, Covered Stents Type); Artery Lesions (Common Iliac Artery Lesions, Severe Calcified Artery Lesions, Complete Obstructive Artery Lesions); End-Use (Hospitals End-Use, Ambulatory Surgery Centers End-Use, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

• Abbott Laboratories
• Alvimedica
• B. Braun Melsungen AG
• Becton, Dickinson and Company (BD)
• Biotronik SE & Co. KG
• Boston Scientific Corporation
• C. R. Bard, Inc.
• Cardinal Health, Inc.
• Cook Medical LLC
• Cordis Corporation
• Endologix LLC
• Getinge AB
• iVascular
• Jotec GmbH
• LeMaitre Vascular, Inc.
• Medtronic plc
• MicroPort Scientific Corporation
• OptiMed Medizinische Instrumente GmbH
• Terumo Corporation
• W. L. Gore & Associates, Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.